In a decade where the dynamic development of targeted therapies and modulation of the immune system for treating cancer has dramatically changed and dominates the armamentarium of an oncologist, the topic the authors of this minireview series have been confronted was challenging: is there anything new in the development of classical cytostatic drugs and their indications? …
